{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:04Z","timestamp":1791357244473,"version":"4.3.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T00:00:00Z","timestamp":1387152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.schres.2013.11.041","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T14:32:19Z","timestamp":1389364339000},"page":"450-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"title":["An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial"],"prefix":"10.1016","volume":"152","author":[{"given":"Suresh","family":"Durgam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Starace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Migliore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Laszlovszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2013.11.041_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"issue":"3","key":"10.1016\/j.schres.2013.11.041_bb0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0022-3956(93)90036-2","article-title":"Validation of the 16-item Negative Symptom Assessment","volume":"27","author":"Axelrod","year":"1993","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2013.11.041_bb0015","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2013.11.041_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/sbi020","article-title":"A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia","volume":"31","author":"Buchanan","year":"2005","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2013.11.041_bb0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability","volume":"9","author":"Citrome","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2\u20133","key":"10.1016\/j.schres.2013.11.041_bb0030","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.schres.2011.07.031","article-title":"Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine","volume":"132","author":"Clark","year":"2011","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2013.11.041_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.schres.2008.07.006","article-title":"Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study","volume":"105","author":"Daumit","year":"2008","journal-title":"Schizophr. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2013.11.041_bb0040","first-page":"140","article-title":"Phase I study of RGH 188 in schizophrenic patients","volume":"11","author":"Ereshefsky","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2013.11.041_bb0045","author":"FDA"},{"issue":"1","key":"10.1016\/j.schres.2013.11.041_bb0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2005.08.010","article-title":"A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls","volume":"80","author":"Goff","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.11.041_bb0055","series-title":"The Abnormal Movement Scale. ECDEU Assessment Manual for Psychopharmacology","first-page":"218","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2013.11.041_bb0060","series-title":"ECDEU Assessment Manual for Psychopharmacology","first-page":"218","article-title":"The clinician global severity and impression scales","author":"Guy","year":"1976"},{"issue":"5","key":"10.1016\/j.schres.2013.11.041_bb0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00210-008-0311-x","article-title":"Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15","volume":"378","author":"Gyerty\u00e1n","year":"2008","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.schres.2013.11.041_bb0065","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","article-title":"Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents","volume":"59","author":"Gyerty\u00e1n","year":"2011","journal-title":"Neurochem. Int."},{"issue":"13","key":"10.1016\/j.schres.2013.11.041_bb0075","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1359-6446(05)03491-4","article-title":"Dopamine D3 receptor antagonists as therapeutic agents","volume":"10","author":"Joyce","year":"2005","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.schres.2013.11.041_bb0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2013.11.041_bb0085","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0010-440X(91)90085-Q","article-title":"SCID\u2013PANSS: two-tier diagnostic system for psychotic disorders","volume":"32","author":"Kay","year":"1991","journal-title":"Compr. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2013.11.041_bb0090","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2013.11.041_bb0095","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2013.11.041_bb0110","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00210-008-0308-5","article-title":"Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15","volume":"378","author":"Kiss","year":"2008","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2013.11.041_bb0105","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"supplement 1","key":"10.1016\/j.schres.2013.11.041_bb0100","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S0920-9964(12)70588-1","article-title":"Cariprazine, a D3\/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics","volume":"136","author":"Kiss","year":"2012","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2013.11.041_bb0115","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","article-title":"Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats","volume":"179","author":"Laszy","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"10.1016\/j.schres.2013.11.041_bb0125","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2013.11.041_bb0120","doi-asserted-by":"crossref","first-page":"S477","DOI":"10.1016\/S0924-977X(13)70756-9","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo- and active-controlled trial","volume":"23","author":"Lieberman","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2013.11.041_bb0130","series-title":"Poster Presented at: the 60th Meeting of the American Psychiatric Association-Institute on Psychiatric Services","article-title":"Use of cariprazine in the treatment of schizophrenia: a proof-of-concept trial","author":"Litman","year":"2008"},{"issue":"2","key":"10.1016\/j.schres.2013.11.041_bb0135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1755-5949.2010.00222.x","article-title":"Antipsychotic occupancy of dopamine receptors in schizophrenia","volume":"17","author":"Nord","year":"2011","journal-title":"CNS Neurosci. Ther."},{"issue":"supplement 3","key":"10.1016\/j.schres.2013.11.041_bb0140","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1016\/S0924-977X(09)70472-9","article-title":"Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients","volume":"19","author":"Potkin","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2013.11.041_bb0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"4","key":"10.1016\/j.schres.2013.11.041_bb0150","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2013.11.041_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \u201cjust the facts\u201d 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr. Res."},{"issue":"S1","key":"10.1016\/j.schres.2013.11.041_bb0160","first-page":"S319","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: a phase III, international, randomized, double-blind, placebo-controlled trial","volume":"38","author":"Zukin","year":"2012","journal-title":"Neuropsychopharm."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413006580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413006580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T11:53:07Z","timestamp":1538913187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996413006580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":32,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0920996413006580"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2013.11.041","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2013.11.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}